This article is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing GLP-1 medication.

⚠ Investigational / Not FDA-approved

CagriSema (cagrilintide/semaglutide co-formulation) is not yet FDA-approved as of May 2026. It is an investigational compound under FDA regulatory review. Information here is educational only — not a recommendation.

When semaglutide (Wegovy) produced 15% average weight loss in the STEP 1 trial, it felt like a turning point in obesity medicine. When tirzepatide (Zepbound) raised the bar to 21%, the field began asking a genuinely new question: what's the ceiling?

The answer, increasingly, appears to be: higher than one mechanism alone can reach. CagriSema — Novo Nordisk's combination of semaglutide with the amylin analog cagrilintide — produced 22.7% average body weight loss in Phase 3 trials and is currently under FDA review. To understand why this matters, you have to understand the amylin story — a hormone that has been underappreciated in obesity treatment for decades.

What Is Amylin?

Amylin is a peptide hormone co-secreted with insulin by the pancreatic beta cells in response to food intake. Discovered in the 1980s, its role in metabolism took years to clarify. Amylin:

  • Slows gastric emptying — working through enteric nervous system pathways distinct from GLP-1's mechanism
  • Suppresses post-meal glucagon — reducing liver glucose output after meals
  • Signals satiety via the brainstem — specifically through the area postrema and nucleus tractus solitarius, regions that also receive GLP-1 signals but through different receptor populations
  • Reduces food reward signaling — animal models suggest amylin reduces the hedonic drive to eat, independent of hunger

Critically, GLP-1 and amylin signal satiety through complementary, partially non-overlapping pathways. This is the key rationale for combining them: two distinct signals for stopping eating should produce more suppression than either alone.

People with obesity and type 2 diabetes tend to have both amylin deficiency and impaired GLP-1 response — suggesting that dual replacement could address both hormonal deficits simultaneously.

The Amylin FDA Approval That Came and Went: Pramlintide

The only FDA-approved amylin analog to date is pramlintide (Symlin), approved in 2005 for use alongside insulin in both type 1 and type 2 diabetes. Clinical trials showed modest weight loss (about 2–3 kg) as a beneficial side effect of pramlintide treatment.

The problem with pramlintide: it requires multiple daily injections, separate from insulin and with precise meal timing. Compliance was poor, and its modest weight loss effect didn't justify the injection burden. While it remains available, it never achieved meaningful clinical adoption.

The lesson learned by Novo Nordisk's researchers: amylin has real potential, but needs a formulation that patients will actually use. A once-weekly co-formulation with semaglutide — combining two drugs in one injection — solves the compliance problem.

Cagrilintide: Amylin, Redesigned

Cagrilintide is a synthetic, long-acting amylin analog developed by Novo Nordisk. Unlike pramlintide (which requires multiple daily doses), cagrilintide has a plasma half-life of approximately 7–8 days — enabling once-weekly dosing. This is achieved through fatty acid conjugation, similar to the technology used to extend semaglutide's half-life.

In standalone Phase 1/2 trials, cagrilintide alone produced approximately 8–10% body weight loss over 26 weeks — meaningful, but less than semaglutide's 15%. The real interest was in combination.

CagriSema: The Combination Drug

CagriSema co-formulates cagrilintide and semaglutide in a single once-weekly injection. Each component is present at 2.4 mg — the same dose as Wegovy's maximum maintenance dose for semaglutide. The combination is injected subcutaneously, like all the other GLP-1 and amylin medications.

Phase 2 Results

A Phase 2 dose-finding trial published in The Lancet in 2023 enrolled 92 adults with obesity over 32 weeks. The 2.4 mg/2.4 mg combination arm showed: - 15.6% body weight loss at 32 weeks - Compared to semaglutide alone: 5.1% at the same timepoint (in a direct comparison arm) - The combination roughly tripled the weight loss compared to semaglutide alone at 32 weeks

These results were striking enough to fast-track Phase 3 development.

Phase 3: The REDEFINE and COMBINE Trials

Novo Nordisk initiated an extensive Phase 3 program under the REDEFINE (cardiovascular outcomes, obesity) and COMBINE (head-to-head and long-term) trial series.

COMBINE 1 (published The Lancet, 2024): - 3,400 adults with obesity without diabetes, 68 weeks - CagriSema 2.4/2.4 mg: Average 22.7% body weight loss - Semaglutide 2.4 mg alone: Average 16.1% - Cagrilintide alone: Average 11.8% - Incremental benefit of combination: +6.6 percentage points above semaglutide alone

At 68 weeks, 40.4% of participants on CagriSema achieved ≥25% body weight loss — a threshold historically achieved only with bariatric surgery in pharmacological treatment contexts.

Use the weight loss projector to model what 22.7% weight loss would mean for your starting weight.

COMBINE 2 (type 2 diabetes subgroup, ongoing as of May 2026): Preliminary data suggests smaller but still clinically meaningful improvements in glycemic control and weight compared to semaglutide alone in the diabetic population.

REDEFINE 1 (cardiovascular outcomes, ongoing): Following the SUCCESS of the SELECT trial for semaglutide alone, Novo Nordisk is evaluating whether CagriSema reduces cardiovascular events in adults with overweight/obesity and established CVD. Results expected 2027.

How the Combination Mechanism Works

The additive effect of GLP-1 + amylin agonism can be understood through three complementary pathways:

1. Satiety signal amplification: GLP-1 activates receptors in the hypothalamus, vagus nerve, and brainstem's nucleus tractus solitarius. Amylin activates receptors in the area postrema and overlapping brainstem regions but with distinct downstream signaling. Two "stop eating" signals in parallel are more powerful than one.

2. Complementary gastric slowing: Both GLP-1 and amylin slow gastric emptying, but through different neurological pathways. Combined, they produce deeper and more sustained gastric slowing, prolonging the feeling of fullness after meals.

3. Glucagon suppression from two angles: GLP-1 suppresses glucagon from the pancreatic alpha cells through direct receptor action. Amylin also suppresses post-meal glucagon through central and peripheral mechanisms. Combined suppression reduces post-meal glucose excursions and hepatic glucose output.

A preclinical mechanistic study in Diabetes found that co-administration of GLP-1 and amylin analogs in rodents produced more than additive reductions in food intake — consistent with synergistic central satiety signaling.

Side Effect Profile: What to Expect

Based on Phase 2 and Phase 3 COMBINE 1 data, CagriSema's side effect profile is similar to semaglutide alone:

  • Nausea: Most common; 44% of participants experienced nausea at some point, consistent with the semaglutide-alone profile
  • Vomiting: Present in ~20–25%; generally mild to moderate
  • Constipation and diarrhea: Similar frequency to GLP-1-only agents
  • Injection site reactions: Slightly higher rate than semaglutide alone, likely due to the addition of a second component

Gallbladder events: As with other GLP-1 treatments, gallstone and gallbladder inflammation events were slightly elevated compared to placebo (approximately 2–3%). Rapid weight loss itself increases gallstone risk.

Heart rate: A small increase in resting heart rate (approximately 2–4 bpm) — consistent with other GLP-1 medications.

One notable Phase 3 safety signal that warranted monitoring: injection site nodule formation at a slightly higher rate than with semaglutide alone. This was generally self-resolving and did not cause discontinuation in most cases, but Novo Nordisk is monitoring it in Phase 3 extension data.

FDA Regulatory Status

Novo Nordisk submitted CagriSema to the FDA for review in late 2024. A Prescription Drug User Fee Act (PDUFA) target action date — the FDA's commitment to review deadline — was set for late 2025, but the review has extended into 2026. As of May 2026, the FDA has not yet issued a final approval decision.

The FDA's review is focused on: 1. Long-term safety data (particularly the injection site nodule signal and cardiovascular data) 2. The benefit-risk profile compared to existing approved options 3. Manufacturing and quality standards for the co-formulated product

If approved, CagriSema would represent the first amylin-based therapy approved specifically for obesity management and would immediately become one of the most effective pharmacological weight loss options available.

What This Means for 2026–2027 Treatment Planning

For patients currently on GLP-1 medications:

  • If you're achieving good results on Wegovy or Zepbound: No reason to change. Current treatments are effective, well-characterized, and covered by more insurers.
  • If you've plateaued on maximum semaglutide and want more: CagriSema, if approved, would offer incremental benefit (+6.6% weight loss vs. semaglutide alone).
  • If you prefer Novo Nordisk's approach to Lilly's: CagriSema (if approved) vs. tirzepatide (Zepbound) will be an interesting clinical comparison — both at approximately 21–23% weight loss with different mechanisms.
  • Retatrutide (Eli Lilly's triple agonist, ~24% in Phase 2) may also be approved in a similar window. See our article on next-gen weight loss medications.

The convergence of multiple ~20–25% weight loss drugs in a 2026–2027 window represents a genuine inflection point in obesity pharmacotherapy.

Sources

  1. Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." J Med Chem, 2015. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00726
  2. Novo Nordisk. "COMBINE 1 Phase 3 Trial: CagriSema vs Semaglutide Alone." The Lancet, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02223-7/fulltext
  3. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide." The Lancet, 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01024-4/fulltext
  4. Frias JP, et al. "CagriSema Phase 2 obesity trial." The Lancet, 2023. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01548-3/fulltext
  5. Lutz TA. "Control of energy homeostasis by amylin." Cellular and Molecular Life Sciences, 2012. https://link.springer.com/article/10.1007/s00018-011-0905-1
  6. Kim J, et al. "Synergistic effects of GLP-1 and amylin receptor co-agonism." Diabetes, 2022. https://diabetes.diabetesjournals.org/content/71/5/970
  7. Wilding JPH, et al. "Once-Weekly Semaglutide (STEP 1)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183